RegulatoryJul 14, 2026, 10:41 AM
Curaleaf First to Register Standardized Cannabis in Spain
AI Summary
Curaleaf Holdings, Inc. announced that the Spanish Agency of Medicines and Medical Devices (AEMPS) has approved the registration of two standardized cannabis preparations. This makes Curaleaf the first company to register under Spain's new regulatory framework, Royal Decree 903/2025, which establishes a national pathway for patient access to standardized cannabis preparations. The registrations enable the supply of these preparations to hospital pharmacies for use in magistral formulas, reinforcing Curaleaf's leadership in the European cannabis market.
Key Highlights
- Curaleaf secured registration for two standardized cannabis preparations (THC-dominant and CBD-dominant) in Spain.
- The company is the first to register under Spain's new regulatory framework, Royal Decree 903/2025.
- Registrations clear the regulatory pathway for supply to hospital pharmacies for magistral formulas.
- Spain's new framework, approved October 2025, establishes a national pathway for patient access.
- Curaleaf operates an EU-GMP certified manufacturing facility and R&D laboratory in Alicante, Spain.
- Curaleaf's Medalchemy SL secured the first license for medicinal cannabis derivatives in Spain in May 2020.
Price Impact
More from CURLF